Treatment with adalimumab (Humira®) now available in Wales

There is progress in Wales regarding an interim policy, published October 2016, for adalimumab (Humira®) for the treatment of adult patients with severe refractory non-infectious uveitis.

You can access the full Welsh interim policy at the link below.

Interim policy for treatment of adult patients in Wales with severe refractory non-infectious uveitis

The big question is: when is England going to catch up with Wales and Scotland (and the rest of the world)?

We were told, back in October 2015, that the published results of the VISUAL 1 and VISUAL 11  studies were required to permit the use of adalimumab to treat severe refractory non-infectious uveitis. Both sets of results are now available. We have been waiting patiently, but NHS England appears to be putting up a road block and looking for excuses for further delays.

NHS England has not yet responded to a jointly-signed letter on this subject, sent some weeks ago from ourselves (BUS), RNIB, Fight for Sight and Olivia’s Vision. There is also no sign of anyone at NHS England taking any notice of the desperate plight that a few of our members who need adalimumab treatment have had to endure for a considerable period of time. Meanwhile, their sight is continuing to deteriorate.

This is a most unsatisfactory state of affairs. BUS will continue to update you on the situation.

 

Diagnosis and Treatment of Birdshot Retinochoroidopathy

Birdshot retinochoroidopathy requires early therapy to limit damage, preserve vision and induce long-term remission.

Akbar Shakoor, MD, and Albert T. Vitale MD, Salt Lake City

– See more at: http://www.revophth.com/content/d/retinal_insider/c/42258/#sthash.UodcC2eS.dpuf

Albert Vitale was one of the speakers at the International Birdshot Symposium held in Boston, USA in September 2013. Continue reading